Association study between the neurexin-1 gene and tardive dyskinesia

Rachel Lanning; Tristram A Lett; Arun K Tiwari; Eva J Brandl; Vincenzo de Luca; Aristotle N Voineskos; Steven G Potkin; Jeffrey A Lieberman; Herbert Y Meltzer; Daniel J Müller; Gary Remington; James L Kennedy; Clement C Zai

doi:10.1002/hup.2568

Association study between the neurexin-1 gene and tardive dyskinesia

Hum Psychopharmacol. 2017 Jan;32(1). doi: 10.1002/hup.2568.

Authors

Rachel Lanning¹, Tristram A Lett^{1

2}, Arun K Tiwari^{1

3}, Eva J Brandl^{1

2}, Vincenzo de Luca^{1

3

4}, Aristotle N Voineskos^{1

3

4}, Steven G Potkin⁵, Jeffrey A Lieberman⁶, Herbert Y Meltzer⁷, Daniel J Müller^{1

3

4}, Gary Remington^{1

3}, James L Kennedy^{1

3

4}, Clement C Zai^{1

3

8}

Affiliations

¹ Neurogenetics Section, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
² Department of Psychiatry, Charité University Medicine Berlin, Berlin, Germany.
³ Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
⁴ Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
⁵ Department of Psychiatry and Human Behavior, University of California, Irvine, California, USA.
⁶ Department of Psychiatry, Mental Health and Neuroscience Center, the University of North Carolina at Chapel Hill School of Medicine, North Carolina, USA.
⁷ Psychiatry and Behavioral Sciences, Pharmacology and Physiology, Chemistry of Life Processes Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁸ Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

PMID: 28120489
DOI: 10.1002/hup.2568

Abstract

Objective: Tardive dyskinesia (TD) is a motor side effect that may develop after long-term antipsychotic treatment. Schizophrenia has recently been associated with the Neurexin-1 (NRXN1) gene that codes for a cell adhesion molecule in synaptic communication.

Methods: This study examined five NRXN1 single-nucleotide polymorphisms (SNPs) for possible association with the occurrence and severity of TD in 178 schizophrenia patients of European ancestry.

Results: We did not find these SNPs to be significantly associated with TD.

Conclusions: More research is needed with additional SNPs and in bigger samples before we can completely rule out the role of NRXN1 in TD.

Keywords: antipsychotics; neurexin-1 (NRXN1); pharmacogenetic; schizophrenia (SCZ); tardive dyskinesia (TD).

MeSH terms

Adult
Antipsychotic Agents / adverse effects*
Calcium-Binding Proteins
Cell Adhesion Molecules, Neuronal / genetics*
Female
Genetic Association Studies / methods*
Humans
Male
Nerve Tissue Proteins / genetics*
Neural Cell Adhesion Molecules
Polymorphism, Single Nucleotide / genetics*
Schizophrenia / drug therapy
Schizophrenia / genetics*
Tardive Dyskinesia / chemically induced
Tardive Dyskinesia / genetics*
White People / genetics

Substances

Antipsychotic Agents
Calcium-Binding Proteins
Cell Adhesion Molecules, Neuronal
NRXN1 protein, human
Nerve Tissue Proteins
Neural Cell Adhesion Molecules

Grants and funding

CIHR/Canada